Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Inagi, R.
Right arrow Articles by Kurokawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inagi, R.
Right arrow Articles by Kurokawa, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 32-33
© 2002 European Renal Association-European Dialysis and Transplant Association

Glomerular Development and Pathology

Mesangial cell-predominant gene, megsin

Reiko Inagi, Toshio Miyata, Toshiyuki Imasawa, Masaomi Nangaku1 and Kiyoshi Kurokawa

Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine, Kanagawa and 1 Division of Nephrology and Endocrinology, University of Tokyo School of Medicine, Tokyo, Japan

Abstract

We identified a novel gene, termed megsin, predominantly expressed in mesangial cells utilizing a 3'-directed regional cDNA library from cultured human mesangial cells. Megsin is a novel serine protease inhibitor (serpin), and the level of megsin RNA/protein expression is up-regulated in patients with IgA nephropathy or diabetic nephropathy, suggesting a link between megsin expression and the pathogenesis of mesangial expansion and/or proliferation. To assess the pathophysiological significance of megsin, we produced human megsin transgenic mice. Genetic manipulation of megsin engenders two elementary mesangial lesions, mesangial expansion and an increase in the number of mesangial cells.

Keywords: diabetic nephropathy; IgA nephropathy; mesangial expansion; serine protease inhibitor (serpin)

Notes

Correspondence and offprint requests to: Reiko Inagi, Institute of Medical Sciences and Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 PhysiologyHome page
A. Gawlik and S. E. Quaggin
Deciphering the Renal Code: Advances in Conditional Gene Targeting
Physiology, October 1, 2004; 19(5): 245 - 252.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm
Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem
J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1927 - 1939.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.